Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 25, 2026, 9:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: OHSU Knight Cancer Institute Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC

NCT04890054
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Fecal Immunochemical Test, Interview, Patient Navigation
Other · Behavioral
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5,696 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jul 25, 2026, 9:04 AM EDT
Terminated Phase 2 Interventional Results available

Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

NCT00022490
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, imatinib mesylate
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Jul 25, 2026, 9:04 AM EDT
Recruiting Phase 1 Interventional

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT03874052
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Secondary Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Punch Biopsy, Questionnaire Administration, Ruxolitinib, Venetoclax
Drug · Procedure · Other
Lead sponsor
Jennifer Saultz
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Columbus, Ohio • Portland, Oregon • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 25, 2026, 9:04 AM EDT
Completed Not applicable Interventional

Humidified Forest Oils for Immune System Recovery in Stage I-III Breast or Prostate Cancer

NCT05012813
View directory record Official record
Conditions
Breast Carcinoma, Prostate Carcinoma
Interventions
Aromatherapy with Essential Oils
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 25, 2026, 9:04 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer

NCT04400903
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8
Interventions
Activity Monitor, Quality-of-Life Assessment, Questionnaire Administration
Device · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
50 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Omaha, Nebraska • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Jul 25, 2026, 9:04 AM EDT
Completed No phase listed Observational

Vascular Response to Brachytherapy Using Functional OCT

NCT01955941
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Not listed
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Jul 25, 2026, 9:04 AM EDT
Completed Not applicable Interventional

Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)

NCT01635413
View directory record Official record
Conditions
Malignant Neoplasm, Postmenopausal
Interventions
Exercise Intervention, Questionnaire Administration
Behavioral · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Jul 25, 2026, 9:04 AM EDT
Terminated Phase 2 Interventional Results available

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

NCT06630325
View directory record Official record
Conditions
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Abemaciclib, Biopsy, Bone Scan, Echocardiography, Exemestane, Gemcitabine, Letrozole, Multigated Acquisition Scan, Osimertinib, Pemetrexed, Survey Administration, Tamoxifen, Biospecimen Collection
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 25, 2026, 9:04 AM EDT
Completed No phase listed Observational

Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis

NCT01556503
View directory record Official record
Conditions
Melanoma
Interventions
VivaScope System
Device
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2016 · Synced Jul 25, 2026, 9:04 AM EDT
Terminated Phase 1 Interventional

Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer

NCT00516542
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole, DHEA, pharmacological study
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Jul 25, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Results available

Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy

NCT00843167
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
broccoli sprout extract, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Jul 25, 2026, 9:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma

NCT05458869
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
HPV Self-Collection, Interview, Survey Administration
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
25 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Jul 25, 2026, 9:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation

NCT01265953
View directory record Official record
Conditions
Prostate Cancer Prevention
Interventions
SFN-rich broccoli sprout extract capsules, Gelatin capsule containing microcrystalline cellulose.
Drug · Dietary Supplement
Lead sponsor
Portland VA Medical Center
Federal
Eligibility
21 Years and older · Male only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Jul 25, 2026, 9:04 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor

NCT07660666
View directory record Official record
Conditions
Melanoma
Interventions
Electronic Health Record Review, Internet-Based Intervention, Patient Navigation, Survey Administration
Other · Behavioral
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 25, 2026, 9:04 AM EDT
Recruiting No phase listed Observational

Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial

NCT07726602
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Non-Interventional Study
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Jul 25, 2026, 9:04 AM EDT
Terminated Early Phase 1 Interventional

Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer

NCT03280277
View directory record Official record
Conditions
Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Ferumoxytol
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Jul 25, 2026, 9:04 AM EDT
Enrolling by invitation No phase listed Observational

Pathogenesis of Hematologic Malignancies

NCT01728402
View directory record Official record
Conditions
Acute Leukemia, Lymphoproliferative Disorders, Myeloproliferative Disorders, Myelodysplastic Syndromes
Interventions
blood draw, bone marrow procedure, or tissue biopsy
Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
1 Year and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 25, 2026, 9:04 AM EDT
Terminated Phase 2 Interventional Results available

Imatinib Mesylate in Treating Patients With Myelofibrosis

NCT00245128
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders
Interventions
imatinib mesylate
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Jul 25, 2026, 9:04 AM EDT
Not yet recruiting Phase 2 Interventional

Mammogram Pretreatment With Ulipristal Acetate

NCT07434128
View directory record Official record
Conditions
Mammography Screening, Breast Density
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Mammogram, Survey Administration, Ulipristal Acetate
Procedure · Other · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 25, 2026, 9:04 AM EDT
Completed Not applicable Interventional

Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma

NCT02359097
View directory record Official record
Conditions
Glioblastoma
Interventions
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadoteridol, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Columbus, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Jul 25, 2026, 9:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercising Together During Radiation Treatment

NCT03418025
View directory record Official record
Conditions
Domestic Partnership, Prostate Carcinoma, Spouse
Interventions
Exercise Intervention, Questionnaire Administration, Survey Administration
Behavioral · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jul 25, 2026, 9:04 AM EDT
Terminated Not applicable Interventional Results available

At-Home Dermoscopy Artificial Intelligence

NCT05321784
View directory record Official record
Conditions
Malignant Skin Neoplasm
Interventions
Dermoscopy, Digital Photography, Self-Skin Examination, Skin Examination with Sklip, Skin Examination, Survey Administration
Other · Procedure · Device
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Jul 25, 2026, 9:04 AM EDT
Recruiting Phase 1 Interventional

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

NCT04659616
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Cytarabine, Daunorubicin, Electrocardiography, Pemigatinib
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Portland, Oregon • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 25, 2026, 9:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

NCT00900055
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Fanconi Anemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
microarray analysis, polyacrylamide gel electrophoresis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, chromatography, high performance liquid chromatography, immunoenzyme technique
Genetic · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
1 Year to 55 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1975 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Jul 25, 2026, 9:04 AM EDT